Throne Biotechnologies

Executive Summary

Throne Biotechnologies is a private cell and gene therapy company developing Stem Cell Educator Therapy (SCE), a first-in-class approach aimed at reversing autoimmune diseases, particularly type 1 diabetes. The technology utilizes autologous stem cells to modulate the immune system, addressing the underlying autoimmune attack on pancreatic beta cells. With over 200 patients treated across clinical trials in Spain, China, and the United States spanning more than a decade, SCE has demonstrated a robust safety profile and encouraging efficacy signals, including improved glycemic control and reduced insulin dependence. The company is currently advancing Phase 2 studies and has the potential to reshape the treatment landscape for diabetes and other autoimmune conditions. Throne's long-term clinical experience positions it favorably for regulatory interactions and potential breakthrough designations. As the company seeks to expand its clinical program and explore pivotal trial designs, upcoming milestones include data readouts from ongoing Phase 2 cohorts and possible discussions with the FDA regarding accelerated approval pathways. The technology's versatility also opens opportunities for application in additional autoimmune indications. While still in mid-stage development, Throne Biotechnologies represents a compelling platform with significant unmet medical need and a strong foundation of clinical evidence, warranting close monitoring by investors and partners in the cell therapy space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout in Type 1 Diabetes70% success
• Q3 2026FDA RMAT Designation for Stem Cell Educator Therapy55% success
• H1 2027Strategic Partnership for Asian Commercialization50% success